José C Crispín1, George C Tsokos. 1. Division of Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
Abstract
PURPOSE OF REVIEW: Interleukin-17 (IL-17) has emerged as a key cytokine involved in the pathogenesis of autoimmune diseases. In this article, we review recently produced evidence obtained in patients and murine models of lupus that link increased IL-17 production with lupus pathology and discuss the potential roles IL-17 may play in the pathogenesis of systemic lupus erythematosus. RECENT FINDINGS: IL-17 may promote autoantibody production and IL-17-producing cells are found in afflicted organs in humans and lupus-prone mice. TH17 and CD3+CD4-CD8- cells are expanded in systemic lupus erythematosus patients and account for the increased production of IL-17. Genetic silencing of genes involved in the increased production of IL-17 in lupus-prone mice as well as treatment of mice with lupus using biologic agents that result in decreased IL-17 production leads invariably to disease mitigation. SUMMARY: The presented evidence strongly argues for the introduction of IL-17-suppressing biologics in the treatment of patients with systemic lupus erythematosus.
PURPOSE OF REVIEW: Interleukin-17 (IL-17) has emerged as a key cytokine involved in the pathogenesis of autoimmune diseases. In this article, we review recently produced evidence obtained in patients and murine models of lupus that link increased IL-17 production with lupus pathology and discuss the potential roles IL-17 may play in the pathogenesis of systemic lupus erythematosus. RECENT FINDINGS:IL-17 may promote autoantibody production and IL-17-producing cells are found in afflicted organs in humans and lupus-prone mice. TH17 and CD3+CD4-CD8- cells are expanded in systemic lupus erythematosuspatients and account for the increased production of IL-17. Genetic silencing of genes involved in the increased production of IL-17 in lupus-prone mice as well as treatment of mice with lupus using biologic agents that result in decreased IL-17 production leads invariably to disease mitigation. SUMMARY: The presented evidence strongly argues for the introduction of IL-17-suppressing biologics in the treatment of patients with systemic lupus erythematosus.
Authors: Niki M Moutsopoulos; Joanne Konkel; Mojgan Sarmadi; Mehmet A Eskan; Teresa Wild; Nicolas Dutzan; Loreto Abusleme; Camille Zenobia; Kavita B Hosur; Toshiharu Abe; Gulbu Uzel; Wanjun Chen; Triantafyllos Chavakis; Steven M Holland; George Hajishengallis Journal: Sci Transl Med Date: 2014-03-26 Impact factor: 17.956
Authors: Cristina Rozo; Yurii Chinenov; Reena Khianey Maharaj; Sanjay Gupta; Laura Leuenberger; Kyriakos A Kirou; Vivian P Bykerk; Susan M Goodman; Jane E Salmon; Alessandra B Pernis Journal: Ann Rheum Dis Date: 2016-11-09 Impact factor: 19.103